TSC22D3 as an immune-related prognostic biomarker for acute myeloid leukemia.

Acute myeloid leukemia (AML) is the type of hematologic neoplasm most common in adults. Glucocorticoid-induced gene regulates cell proliferation through its function as a transcription factor. However, there is no consensus on the prognostic and immunoregulatory significance of in AML. In the present study, we evaluated the correlation between expression, immunoinfiltration, and prognostic significance in AML. Knockdown of significantly attenuated the proliferation of Hel cells and increased sensitivity to cytarabine (Ara-c) drugs. Furthermore, reduced the release of interleukin-1β (IL-1β) by inhibiting the NF-κB/NLRP3 signaling pathway, thereby inhibiting macrophage polarization to M1 subtype, and attenuating the pro-inflammatory tumor microenvironment. In conclusion, this study identified as an immune-related prognostic biomarker for AML patients and suggested that therapeutic targeting of may be a potential treatment option for AML through tumor immune escape.